Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) Director Stephanie Okey sold 17,500 shares of Crinetics Pharmaceuticals stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $46.38, for a total value of $811,650.00. Following the completion of the sale, the director now owns 6,000 shares of the […]
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) Director Stephanie Okey sold 17,500 shares of the business’s stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $46.38, for a total transaction of $811,650.00. Following the completion of the sale, the director now owns 6,000 shares in the […]
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) COO Jeff E. Knight sold 32,359 shares of Crinetics Pharmaceuticals stock in a transaction dated Friday, March 22nd. The stock was sold at an average price of $44.31, for a total value of $1,433,827.29. Following the completion of the sale, the chief operating officer now owns 52,580 […]
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) Director Matthew K. Fust sold 60,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $44.14, for a total transaction of $2,648,400.00. Following the completion of the sale, the director now directly owns […]
Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) had its price objective lifted by research analysts at Oppenheimer from $46.00 to $48.00 in a research note issued on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s price target would indicate a potential upside of 7.50% from the stock’s previous close. […]